Invited Speakers
Keynote | ||
---|---|---|
Angelo De Marzo MD, Ph.D.Professor, Associate Director of Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins UniversityTopic : Tissue-based biomarker measurements in immune-oncology: where are we at and where we are heading |
CV | |
Perspectives on Current Trends & Future Opportunities | ||
Qinhua Cindy Ru Ph.D.EVP, Chief Scientific Officer, CARsgen TherapeuticsTopic : Fill the Gap and Share the Success |
CV | |
Eric Tsao Ph.D.CEO, Synermore BiologicsTopic : Development of Anti-Rabies MAbs for Post-Exposure Prophylaxis |
CV | |
Emerging Targets | ||
Yoram Reiter Ph.D.Professor & Head, Laboratory of Molecular Immunology, Technion-Israel Institute of TechnologyTopic : Engineering Immune Effector Molecules for the Development of Novel Immunotherapies for Cancer and Autoimmunity |
CV | |
Yan Wu Ph.D.Director and Principal Scientist, GenentechTopic : Therapeutic Antibody Discovery at Genentech |
CV | |
Technologies for Antibody Discovery, Engineering, and Manufacture | ||
Partha S. Chowdhury Ph.D.Senior Director and Head, Antibody Discovery at Sanofi GenzymeTopic : Technologies and their role in the evolution of therapeutic antibodies |
CV | |
Tian-Lu Cheng Ph.D.Distinguished Professor/Director, Kaohsiung Medical UniversityTopic : XenoComputer: Develop fully humanized antibody drugs by computer-aided human V(D)J recombination |
CV | |
Gregory P. Adams Ph.D.Chief Scientific Officer, Eleven BiotherapeuticsTopic : Developing Targeted Fusion Proteins for the Treatment of Cancer |
CV | |
Karen Wen Ph.D.CEO of Mycenax BiotechTopic : From TuNEX to LusiNEX, Biologics development in Taiwan |
CV | |
Translation and Development of Antibody Therapeutics | ||
Larry Lo Ph.D.Sr. Director R&D, Corvidia TherapeuticsTopic : Biomarker Strategy for Therapeutic Antibody In Early Clinical Development |
CV | |
Meng-Hsin Chen Ph.D.VP, R&D, TaiMed BiologicsTopic : Insights from a Success Story of a Local Biotech Leader: Development of Ibalizumab ~the 1st Monoclonal Antibody for HIV Treatment |
CV | |
James Chih-Hsin Yang MD, Ph.D.Professor & Director, Graduate Institute of Oncology, College of Medicine, National Taiwan UniversityTopic : PD1/PDL1 checkpoint inhibitor therapy and their roles in the cancer immunotherapy |
CV |